semaglutide and graves disease Tirzepatide Disease: Safety and Clinical Considerations semaglutide thyroid issues semaglutide and

It has been licensed for aiding weight loss in non-diabetic people under the trade name Wegovy, strictly indicated for patients with obesity or overweight with diagnosed weight-related comorbidities [6, 7]

There is no recovery time required after each injection

Im cautiously optimistic, said Meghan Garcia-Webb, MD, triple board certified in internal medicine, lifestyle medicine, and obesity medicine

Upon approval, the weight loss professional will initiate semaglutide treatment at a low dosage, gradually increasing to around 2.4mg per week

Only Wegovy has been approved for the treatment of obesity but other GLP-1 medications like Ozempic, Mounjaro, Saxenda and Victoza have been used as off-label weight loss treatments